# Is use of e-cigarettes an effective and safe smoking cessation method?

#### **Charlotta Pisinger**

Professor in tobacco and nicotine prevention
University of Southern Denmark
Center for Clinical Research and Prevention






**TrygFonden** 



### I have nothing to declare

#### ANNUAL GLOBAL PREVENTABLE DEATHS



#### Chronic Diseases

Stroke

Cancers

Oropharynx

Esophagus-

Larynx

Liver -

Pancreas

Kidney and ureter

Cervix

Bladder

Colorectal

Blindness, cataracts, age-related macular degeneration Congenital defects-maternal smoking: orofacial clefts

Periodontitis

Aortic aneurysm, early abdominal aortic atherosclerosis in young adults

Coronary heart disease

Pneumonia

Atherosclerotic peripheral vascular disease

Chronic obstructive pulmonary disease, tuberculosis, asthma, and other respiratory effects

#### Diabetes

Reproductive effects in women (including reduced fertility)

Hip fractures

Ectopic pregnancy

Male sexual function-erectile dysfunction

Rheumatoid arthritis

Immune function

Overall diminished health

#### How e-cigarettes changed my life

Demand for electronic cigarettes is booming, but experts are not convinced they help people to quit smoking. Whatever the

case, I am still "Quitting smoking was the easiest thing I've ever done, thanks to electronic cigarettes"

▲ For Stephanie Rafanelli e-cigarettes were an electric lightbulb moment in the struggle to give up tobacco. Photograph: Linda Nylind for the Guardian

t all started quite early on. My first words, uttered with a not-socherubic look on my face and a strange baby puffing sound, were: "Light! Light!" It was as if I had come out of the birth canal sucking not on my thumb, but a mini-Marlboro. Much excitement and hand-

#### ow the Electronic Cigarette Changed My Life

OR TRAIL

#### the Electronic Cigarette Changed My Life

oking when I Growing up orhood in evervone nad its pluses ong lost nd of mine d aot me ttes. At first



When the digital electronic cigarette first car I would get to have my next smoke. notice cigarettes taking over my entire life. It given them a try, but they weren't very good, did retty soon I was making plans to sneak out to por, didn't taste anything like a real analog cigare

Growing up, you could smoke at work, in res pretty much wherever you wanted, and it seeme smoked around me, too. But now, tons of people was banned everywhere, it was way too expens could stand the smell of you around them, and vo to planning, scheming, and wondering when you your next smoke, using gum and something to he smell, and it was taking more and more time and I wanted to quit, but everything I tried didn't wor believe these stupid cigarettes were so impossib the health issues started, one after another, I w tails on the health issues, but I knew I had to fin

#### Vaping saved my life

Toni Brown - 11:00, Mar 30 2017











# 2 factors are important before recommending a therapy





### THE EFFECT



Randomized controlled trials
- clinical setting/research
centers/smoking cessation clinic



Observational studies
-real world

### Real world studies




## Systematic reviews of longitudinal studies:

- Use of e-cigarettes in a real world setting does not help smokers to quit
  - Might be effective in daily users
    - But most use e-cigarettes as consumer/lifestyle product
  - Low evidence

# Example of a review of observational studies

- 18 studies
- Almost 40,000 smokers
- Follow-up time: 6 months to 4 years
- Mostly: no information on participants' motivation to quit
- E-cigarette use was not associated with abstinence



Behavioral part
Psychological dependence



**Chemical part** 

Physical dependence

#### Counselling



Psychological dependence

### Best treatment





**Bupropion** 



Physical dependence

Nicotine replacement combination therapy





#### E-cigarettes are more effective than nicotine-replacement therapy in helping smokers quit

17 NOV 2022 SHARE THIS

PUBLISHED

HEALTH MEDICAL SCIENCES RESEARCH

The latest Cochrane Review finds high certainty evidence that nicotine e-cigarettes are more effective than traditional nicotine-replacement therapy (NRT) in helping people quit smoking. Oxford co-led study finds Britons in favour of EDI initiatives but with renewed approach 23 MAR 2024



Major new project will harness Al to transform how zeroemission buildings are designed 22 MAR 2024



New funding for development of world's first lung cancer vaccine 22 MAR 2024



Al ethics are ignoring children, say Oxford researchers 21 MAR 2024



New study highlights troubling trends in midlife mortality in the US and UK



21 MAR 2024

#### DISCOVER MORE

- · Support Oxford's research
- · Partner with Oxford on research

# Clinical setting: comparing with nicotine replacement therapy (Cochrane review)

- 8 trials included
- 60% higher odds to quit with e-cigarettes than with NRT
  - significant
- Evidence graded as HIGH



	EC		NRT		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.1.1 Not selected on p	pregnancy						
Bullen 2013	21	289	17	295	12.7%	1.26 [0.68, 2.34]	-
Hajek 2019	79	438	44	446	32.9%	1.83 [1.30, 2.58]	-
Klonizakis 2022	36	84	25	82	19.1%	1.41 [0.93, 2.12]	-
Lee 2018	5	20	1	10	1.0%	2.50 [0.34, 18.63]	
Myers-Smith 2022	13	68	2	67	1.5%	6.40 [1.50, 27.30]	
Russell 2021 (1)	44	145	15	71	15.2%	1.44 [0.86, 2.40]	-
Russell 2021 (2)	34	140	15	70	15.1%	1.13 [0.66, 1.94]	<u> </u>
Subtotal (95% CI)		1184		1041	97.6%	1.58 [1.29, 1.93]	♦
Total events:	232		119				•
Heterogeneity: Chi <sup>2</sup> = 6	6.91, df = 6 (F	= 0.33); 1	2 = 13%				
Test for overall effect:	Z = 4.49 (P <	0.00001)					
1.1.2 Pregnant popula	ition						
Hajek 2022 (3)	6	169	3	150	2.4%	1.78 [0.45, 6.97]	
Subtotal (95% CI)		169		150	2.4%	1.78 [0.45, 6.97]	
Total events:	6		3				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 0.82 (P =	0.41)					
Total (95% CI)		1353		1191	100.0%	1.59 [1.30 , 1.93]	•
Total events:	238		122				\ <b>*</b>
Heterogeneity: Chi <sup>2</sup> = 6	6.96, df = 7 (F	9 = 0.43); 1	2 = 0%				0.01 0.1 1 10 10
Test for overall effect:	Z = 4.57 (P <	0.00001)					Favours NRT Favours EC
Test for subgroup differ	rences: Chi <sup>2</sup> =	= 0.03, df =	= 1 (P = 0.8	7), I <sup>2</sup> = 0%	ó		



# Clinical setting: comparing with nicotine replacement therapy (other recent reviews)

	Country	Min. 6 months follow-up	Studies with COI excluded	Unpublished studies included	Number of studies	Risk ratio (RR) (95% CI)	Level of evidence
Lindson N (Cochrane)	UK	Yes	No	Yes	8	1.59 (1.29 -1.93)	High
Chan GCK	Australia	No	No	No	4	1.49 (1.09-2.04)	Not assessed
Pound CM	Canada	No	No	No	5	1.42 (0.97-2.09)	Low
Li J	China	Yes	No	No	5	1.67 (1.21-2.28)	Low
Grabovac I	Austria	No	No	No	3	1.69 (1.25–2.27)	Low
Quigley J	Irland	Yes	No	No	8	1.17 (0.66-1.86)	Low
Vanderkam	France	Yes	No	No	3	1.49 (1.14–1.95)	Not assessed
Banks E	Australia	Yes	Yes	No	3	1.25 (0.74-2.11)	Low

# Clinical setting: comparing with varenicline or cytisine or bupropion

1 small varenicline study

**Cochrane** Database of Systematic Reviews

- Varenicline significantly better
- Evidence graded as: very low


Nicotine EC		Varenicline		Risk Ratio	Risk I	Ratio	
Study or Subgroup	Events	Total	Events	Total	M-H, Fixed, 95% CI	M-H, Fixed	d, 95% CI
Ioakeimidis 2018	4	27	13	27	0.31 [0.11, 0.82]		
	Cochi	rane				.01 0.1 1 ours varenicline	10 100 Favours nicotine EC



- E-cigarettes + varenicline vs.
   varenicline
- The trial was stopped early due to COVID-19 restrictions and a varenicline recall

Tattan-Birch et al. Nicotine and Tobacco Research, 2023, 25, 395–403

## Cochrane review: comparing with placebo/no treatment



# Cochrane review: The same effect of e-cigarettes and pharmacotherapy





**E-cigarette** 



Cytisine



Nicotine replacement combination therapy





**Bupropion** 



# Clinical setting: comparing with counselling or no support

- 7 studies included
- Almost 2 times higher probability to quit with e-cigarettes
  - significant
- Evidence graded as LOW

Nicotine EC		ne EC	Usual	care		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI	
Begh 2021	7	164	3	161	2.1%	2.29 [0.60 , 8.70]	_		
Carpenter 2023	58	427	17	211	15.7%	1.69 [1.01, 2.82]		-	
Dawkins 2020	3	48	0	32	0.4%	4.71 [0.25 , 88.30]		<u> </u>	
Eisenberg 2020	5	128	1	121	0.7%	4.73 [0.56 , 39.88]	_	<u> </u>	
ESTxENDS Trial (1)	186	620	105	640	71.1%	1.83 [1.48 , 2.26]			
Halpern 2018	4	1199	0	813	0.4%	6.11 [0.33 , 113.24]		<del>-</del>	
Holliday 2019 (2)	6	40	2	40	1.4%	3.00 [0.64 , 13.98]	_		
Lucchiari 2022	15	70	10	70	6.9%	1.50 [0.72 , 3.11]	_	-	
Pratt 2022	6	120	2	120	1.4%	3.00 [0.62 , 14.57]	_	<del>  -</del>	
Total (95% CI)		2816		2208	100.0%	1.88 [1.56 , 2.25]		•	
Total events:	290		140					<b>'</b>	
Heterogeneity: Chi <sup>2</sup> = 3	.09, df = 8 (I	P = 0.93); ]	[2 = 0%]				0.01 0.1	1 10 100	
Test for overall effect: Z	Z = 6.70 (P <	0.00001)					Favours usual care	Favours nicotine EC	



Test for overall effect: Z = 6.70 (P < 0.00001) Test for subgroup differences: Not applicable



### Switching is not quitting




# 70% of participants continued using e-cigarettes after 6-12 months

- not rid of addiction
- not the health benefits of quitting
- best-case: reduction in health damage

Butler AR et al. Prev Med 2022;165

### New e-cigarette smoking cessation study Auer 2024



Auer R et al. N Engl J Med 2024; 390: 601-610.

### ... important things to consider

- Selected persons participate in clinical trials
  - More motivated to quit

Healthier

Younger





Users were also offered counseling

### ... important things to consider

- Generally: low quit rates with e-cigarettes
  - Typically only 10-20% quit



### THE SAFETY

# Safety considerations: recommended duration of use

#### Short-term use

Varenicline



**Bupropion** 



Cytisine



Nicotine replacement combination therapy





Long-term use

**E-cigarette** 



# Serious adverse events in smoking cessation trials

- 1 year follow-up or shorter
- No significant difference between NRT and ecigarettes in trials
- But a tendency of a higher risk in e-cigarette users, except in a pregnancy study



	EC		NRT			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events Total		Weight M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
1.3.1 4 weeks								
Lee 2018 (1)	0	19	0	10		Not estimable		
Subtotal (95% CI)		19		10		Not estimable		
Total events:	0		0					
Heterogeneity: Not app	olicable							
Test for overall effect:	Not applicable	e						
1.3.2 12 weeks								
Wagener 2023	18	175	10	175	12.3%	1.80 [0.86, 3.79]	<del> </del>	
Subtotal (95% CI)		175		175	12.3%	1.80 [0.86, 3.79]		
Total events:	18		10				•	
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 1.55 (P =	0.12)						
1.3.3 6 months								
Bullen 2013	24	241	14	215	18.2%	1.53 [0.81, 2.88]	<del> </del> _	
Myers-Smith 2022	0	60	0	47		Not estimable		
Subtotal (95% CI)		301		262	18.2%	1.53 [0.81, 2.88]		
Total events:	24		14					
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 1.32 (P =	0.19)						
1.3.4 1 year								
Hajek 2019	27	356	19	342	23.8%	1.37 [0.77, 2.41]	<b></b>	
Subtotal (95% CI)		356		342	23.8%	1.37 [0.77, 2.41]		
Total events:	27		19					
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 1.07 (P =	0.28)						
1.3.5 3 months after e	nd of pregna	ncy						
Hajek 2022	31	564	37	557	45.7%	0.83 [0.52 , 1.31]		
Subtotal (95% CI)		564		557	45.7%		<u>.</u>	
Total events:	31		37				7	
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 0.80 (P =	0.42)						
Total (95% CI)		1415		1346	100.0%	1.20 [0.90 , 1.60]	•	
Total events:	100		80			•	•	
Heterogeneity: Chi <sup>2</sup> = 4	4.38, df = 3 (F	9 = 0.22);	$I^2 = 32\%$			0.0	01 0.1 1 10	
Test for overall effect:	Z = 1.27 (P =	0.20)				0.0	Favours EC Favours NRT	
Test for subgroup differ			= 3 (P = 0.2	2), I <sup>2</sup> = 31.	.6%			

### Safety considerations: adverse events









## E-cigarettes

Current evidence

### Are E-cigs safe?

E-cigarettes are significantly less harmful (95%) to health than smoking tobacco



### Background research paper for the PHE report



#### **Research Report**



Eur Addict Res 2014;20:218–225 DOI: 10.1159/000360220 Received: December 23, 2013 Accepted: January 30, 2014 Published online: April 3, 2014

# A limitation of this study is the lack of hard evidence for the harms of most products on most of the criteria.

David J. Nutt<sup>a</sup> Lawrence D. Phillips<sup>b</sup> David Balfour<sup>f</sup> H. Valerie Curran<sup>c</sup> Martin Dockrell<sup>d</sup> Jonathan Foulds<sup>h</sup> Karl Fagerstrom<sup>i</sup> Kgosi Letlape<sup>k</sup> Anders Milton<sup>j</sup> Riccardo Polosa<sup>l</sup> John Ramsey<sup>e</sup> David Sweanor<sup>g</sup>

<sup>a</sup>Imperial College London, UK; <sup>b</sup>Department of Management, London School of Economics and Political Science, and Facilitations Ltd., UK; <sup>c</sup>University College London, UK; <sup>d</sup>Action on Smoking and Health London, UK; <sup>e</sup>TICTAC Communications Ltd. at St. George's, University of London, London, UK; <sup>f</sup>University of Dundee, Dundee, UK; <sup>g</sup>Faculty of Law, University of Ottawa, Ottawa, Canada; <sup>h</sup>Pennsylvania State University, College of Medicine, Hershey Pa., USA; <sup>i</sup>Fagerström Consulting, Vaxholm, Sweden; <sup>j</sup>World Medical Association, Milton Consulting, Stockholm, Sweden; <sup>k</sup>World Medical Association, Johannesburg, South Africa; <sup>i</sup>Centre for the Prevention and Cure of Tobacco Use, University of Catania, Catania, Italy

Some of the authors have a conflict of interest with the tobacco industry



# E-cigarettes

Current evidence

### Are E-cigs safe?

Update in 2022

"...we believe that the 'at least 95% less harmful estimate' remains broadly accurate at least over short- and medium-term periods" (<one year)

### Short term eksperimental studies

Some short-term studies show potential health benefits of switching

- Example:
- 186 participants
- 6 weeks randomized controlled trial
  - Intervention: e-cigarette with flavors, 5% nicotine + brief education
  - Control: continue smoking
- Results:
  - E-cigarette group: significantly greater reductions in NNAL(carcinogen), carbon monoxide and respiratory symptoms











### No studies with sufficiently long-term follow-up



- Most comprehensive reviews:
- NASEM report. US 2018
- Australian report. 2022
- +189 studies
- Health outcomes
- Human studies only
- "The impact of e-cigarettes on important clinical health outcomes (...) is not known, as reliable evidence is lacking."

Banks E. et al. Electronic cigarettes and health outcomes: systematic review of global evidence. Report for the Australian Department of Health. 2022


	Health outcome	Meta- analyses	Randomised controlled trial	Cohort study	Non- randomised intervention study	Case- control study	Surveillance report	Cross- sectional survey	Case series	Case report
	Dependence and abuse liability		13 7/6	1 0/1	17 9/8			20 11/9		
	Cardiovascular health outcomes	1 0/1	11 3/8	1 0/1	6 5/1			8 1/7		1 0/1
	Cancer			1 1/0				2 1/1		3 2/1
	Respiratory health outcomes*		9 5/4	5 2/3	5 1/4		18 0/18	21 4/17	11 0 / 11	26 0/26
	Oral health			2 1/1	2 2/0			19 1/18		1 0/1
	Developmental and reproductive effects			2 0/2				1 0/1		
	Burns and injuries						7 1/6		24 14/10	16 5/11
	Poisoning						25 13 / 12		4 2/2	23 14/9
	Mental health effects			1 0/1				8 0/8		
	Environmental hazards with health implications**				17 9/8		2 0/2		5 0/5	
	Neurological outcomes						3 0/3		2 0/2	7 1/6
	Sleep outcomes							4 0/4		
า	Less serious adverse events		11 3/8	3 1/2	2 2/0		1 0/1	3 0/3		
	Optical health				1 0/1			1 0/1		
	Wound healing									2 0/2
	Olfactory outcomes							1 0/1 2		
	Endocrine outcomes	ivallibers in green relate to evidence most								
	Allergic diseases Haematological							2 0/2	1 0/1	3 2/1
	outcomes									2 0/2

### Conclusive evidence on short-term effects


#### Negative immediate and short-term health effects

- addiction
- throat irritation, nausea
- poisoning, injuries, burns
- seizures
- increased heart rate and blood pressure
- increased arterial stiffness
- EVALI
  - (acute lung injury (cannabis oil/vitamin E related in 8 of 10 cases))





## Tobacco industry related papers almost never find potentially harmful effects of vaping



Pisinger C. et al. A conflict of interest is strongly associated with tobacco industry-favourable results, indicating no harm of e-cigarettes. Prev Med. 2019 Feb;119:124-131.

## Toxicity and biological effects

#### Animal studies


- higher mortality when exposed to infections
- DNA damage
- lung cancer
- impaired kidney development
- cardiac arrhythmia
- arterial dysfunction
- cerebrovascular dysfunction
- lung dysfunction
- airway inflammation
- asthma
- ...



- Content of fluid/vapor: many toxic and carcinogenic compounds
- Cell studies: inflammation, cytotoxicity/cell death, oxidative stress...




## Cardiovascular system: biological effects and pathways



Kennedy C et al. Preventive Medicine 127 (2019) 105770

## Pulmonary system: biological effects



Davis LC et al. Eur Respir Rev 2022; 31: 210121

### First meta-analysis on health effects of e-cigarettes

- Meta-analysis of 107 very large population-based surveys
- 30 longitudinal studies
  - same findings as the crosssectional studies
  - most adjusted for smoking



## Risk of disease in e-cigarettes users compared with cigarette users




 Cardiovascular disease, stroke, metabolic disease: no difference in odds of disease




- Lung disease: lower risk in e-cig users
  - asthma: 16% lower odds in e-cig users
  - COPD: 47% lower odds in e-cig users
- Oral disease: lower risk in e-cig users
  - 13% lower odds in e-cig users

Glantz et al. NEJM Evid 2024;3(3) DOI: 10.1056/EVIDoa2300229

## **Switching**



## Many/most e-cigarette users in the general population also smoke = "dual users"



#### E-cigarettes, population-based surveys:

39% in the USA, adults, Mayer M, JAMA Netw Open 2020 ;3:e2020694-E2020694

45% in UK. <a href="https://smokinginengland.info/graphs/e-cigarettes-latest-trends">https://smokinginengland.info/graphs/e-cigarettes-latest-trends</a>. 2022

56% in USA, men. Okunna N. American journal on addictions, 2021, Vol.30(2), p.138-146

57% in Europe, adluts. IJERPH. 2020 Mar 17;17(6):1971

67% in Sweden. Hedman L. JAMA Netw Open 2018, 1(3):e180789.


**85%** in South Korea. Kim CY. *Sci Rep* 2020, 10(1):5612.

## Prof Robert West, BBC "Inside Health" Feb 2016 http://www.bbc.co.uk/programmes/b070dq8h



#### Cutting down "not much"

10m40s: "We know that most people who use ecigarettes are continuing to smoke and when you ask them they tell you that they are mostly doing that to cut down the amount they smoke. But we also know they are smoking, it's not really that much different from what they would have done since they started using ecigarettes."



## Risk of disease in dual users compared with exclusive cigarette users

 Dual use associated with 20-40% higher odds of disease compared with exclusive smoking

Table 1. Pooled Adjusted* Odds Ratios of Each Disease Outcome (95% Confidence Intervals) from the Meta-analyses.							
Comparisons	Cardiovascular	Stroke	Metabolic Dysfunction	Asthma	COPD	Oral Disease	
Comparison to cigarette use							
E-cigarettes vs. cigarettes	0.81 (0.58-1.14)	0.73 (0.47–1.13)	0.99 (0.91–1.09)	0.84 (0.75–0.95)	0.53 (0.38–0.74)	0.87 (0.76–1.00)	
Dual use vs. cigarettes	1.23 (0.99–1.54)	1.26 (1.06–1.50)	1.22 (1.15–1.31)	1.20 (1.12–1.28)	1.41 (1.12–1.64)	1.27 (1.15–1.39)	
Comparison to no use							
E-cigarette vs. nonuse	1.24 (1.05–1.46)	1.32 (0.99–1.76)	1.25 (1.18–1.33)	1.24 (1.19–1.30)	1.46 (1.31–1.61)	1.47 (1.19–1.82)	
Dual use vs. nonuse	2.23 (1.59–3.14)	2.39 (2.02–2.83)	1.49 (1.17–1.91)	1.56 (1.22–2.00)	3.29 (1.97–5.51)	1.78 (1.49–2.12)	
Cigarette vs. nonuse	1.64 (1.24–2.16)	2.08 (1.91–2.27)	1.27 (1.17–1.37)	1.56 (1.34–1.80)	2.99 (2.29–3.92)	1.69 (1.40–2.03)	

Glantz et al. NEJM Evid 2024;3(3) DOI: 10.1056/EVIDoa2300229


## How do we help the (old) heavy smokers who do not want to quit?



#### Hospital setting

- Cochrane review states that e-cigarettes are more effective than NRT
- Some experiments show health benefits when smokers switch
- An alternative for the heavy smoker who will not quit?





#### We know what works

#### Evidence based

High long-term quit rates can be achived

Repeated (5-6 (up to 8)) smoking cessation counseling sessions



Varenicline, cytisine or combined nicotine replacement therapy









#### **Effective AND safe**

	Effective	Safe
Counseling	Yes	Yes
Varenicline, cytisine, combination nicotine replacement	Yes	Yes
E-cigarettes	Yes (probably)	No (+ high risk of dual use)

## Recommendations for smoking cessation

 Do not recommend ecigarettes



Hippocratic Oath: First, do no harm

# Thank you for your attention

charlotta.pisinger@regionh.dk

